Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Roseville, CA
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Sutter Roseville Medical Center
mi
from
Roseville, CA
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Lafayette, CO
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Rock Creek
mi
from
Lafayette, CO
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Lowell, MA
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Lowell General Hospital
mi
from
Lowell, MA
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Topsham, ME
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Maine Center for Cancer Medicine-Topsham
mi
from
Topsham, ME
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Kinston, NC
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Vidant Oncology-Kinston
mi
from
Kinston, NC
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Eau Claire, WI
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
HSHS Sacred Heart Hospital
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Decatur, IL
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Cancer Care Specialists of Illinois - Decatur
mi
from
Decatur, IL
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Detroit, MI
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Sylvania, OH
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Promedica Flower Hospital
mi
from
Sylvania, OH
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Novi, MI
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Ascension Providence Hospitals - Novi
mi
from
Novi, MI
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Southfield, MI
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Ascension Providence Hospitals - Southfield
mi
from
Southfield, MI
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Bemidji, MN
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Sanford Joe Lueken Cancer Center
mi
from
Bemidji, MN
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Dayton, OH
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Oconto Falls, WI
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Marshfield, WI
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Marshfield
mi
from
Marshfield, WI
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Dayton, OH
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Dayton Physician LLC-Miami Valley Hospital North
mi
from
Dayton, OH
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Rice Lake, WI
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Rice Lake
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Saginaw, MI
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Fargo, ND
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated:  12/31/1969
mi
from
Danville, VA
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Enrolling
Updated: 12/31/1969
Danville Regional Medical Center
mi
from
Danville, VA
Click here to add this to my saved trials
A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
A Phase II Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
Status: Enrolling
Updated:  12/31/1969
mi
from
Atlanta, GA
A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
A Phase II Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
A Phase II Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
Status: Enrolling
Updated:  12/31/1969
mi
from
Atlanta, GA
A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
A Phase II Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Emory University Winship Cancer Institutute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Little Rock, AR
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
San Diego, CA
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Rady Children's Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Hartford, CT
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Connecticut Children's Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Orlando, FL
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Arnold Palmer Hospital for Children
mi
from
Orlando, FL
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Honolulu, HI
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Grand Rapids, MI
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Helen DeVos Children's Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Minneapolis, MN
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Kansas City, MO
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospitals and Clinics
mi
from
Kansas City, MO
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Charlotte, NC
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Levine Children's Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Hershey, PA
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center and Children's Hospital
mi
from
Hershey, PA
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Charleston, SC
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Nashville, TN
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Monroe Carrell Jr Children's Hospital at Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Austin, TX
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Dell Children's Blood and Cancer Center
mi
from
Austin, TX
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Houston, TX
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Texas Children's Cancer and Hematology Centers
mi
from
Houston, TX
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Salt Lake City, UT
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Primary Children's Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Saint Louis, MO
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Cardinal Glennon Children's Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Portland, OR
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Randall Children's Hospital
mi
from
Portland, OR
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Beirut,
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
American University of Beirut Medical Center
mi
from
Beirut,
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
mi
from
Bronx, NY
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors
Cellular Proliferation Imaging Using [18F] Fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors
Status: Enrolling
Updated:  12/31/1969
mi
from
Seattle, WA
18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors
Cellular Proliferation Imaging Using [18F] Fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
Randomized Metabolic Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma FDOPA PET-CT
Status: Enrolling
Updated:  12/31/1969
mi
from
Houston, TX
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
Randomized Metabolic Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma FDOPA PET-CT
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Research Institute PET Center
mi
from
Houston, TX
Click here to add this to my saved trials
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Status: Enrolling
Updated:  12/31/1969
mi
from
Philadelphia, PA
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer
Status: Enrolling
Updated:  12/31/1969
mi
from
Tampa, FL
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
Status: Enrolling
Updated:  12/31/1969
mi
from
Durham, NC
IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy
A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection
Status: Enrolling
Updated:  12/31/1969
mi
from
Columbus, OH
Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy
A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection
Status: Enrolling
Updated: 12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma
Feasibility, Validation and Differentiation of Induced Pluripotent Stem Cells Produced From Patients With Heritable Retinoblastoma
Status: Enrolling
Updated:  12/31/1969
mi
from
Memphis, TN
Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma
Feasibility, Validation and Differentiation of Induced Pluripotent Stem Cells Produced From Patients With Heritable Retinoblastoma
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)
Status: Enrolling
Updated:  12/31/1969
mi
from
Tampa, FL
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)
Status: Enrolling
Updated:  12/31/1969
mi
from
Columbus, OH
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials